Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OCGN
stocks logo

OCGN

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
350.00K
-69.33%
-0.057
+41.67%
300.00K
-73.59%
-0.060
+20%
375.00K
-50.92%
-0.060
+20%
Estimates Revision
The market is revising Upward the revenue expectations for Ocugen, Inc. (OCGN) for FY2025, with the revenue forecasts being adjusted by 69.85% over the past three months. During the same period, the stock price has changed by 98.58%.
Revenue Estimates for FY2025
Revise Upward
up Image
+69.85%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-10.26%
In Past 3 Month
Stock Price
Go Up
up Image
+98.58%
In Past 3 Month
3 Analyst Rating
up Image0
Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 6.33 USD with a low forecast of 4.00 USD and a high forecast of 8.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 1.090
sliders
Low
4.00
Averages
6.33
High
8.00
up Image0
Current: 1.090
sliders
Low
4.00
Averages
6.33
High
8.00
H.C. Wainwright
Buy
downgrade
$8 -> $7
2025-05-12
Reason
H.C. Wainwright
Price Target
$8 -> $7
2025-05-12
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Ocugen to $7 from $8 and keeps a Buy rating on the shares following the Q1 report. The firm says the company is targeting OCU400 approval in 2026.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$8
2025-03-06
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$8
2025-03-06
Reiterates
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$6 → $7
2025-03-06
Reason
Chardan Capital
Daniil Gataulin
Price Target
$6 → $7
2025-03-06
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$7 → $8
2025-02-13
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$7 → $8
2025-02-13
Maintains
Strong Buy
Reason
Latest data shows the largest indicative borrow rate increases among liquid option names include: Azul (AZUL) 70.69% +1.20, Soho House + Co Inc (SHCO) 1.61% +0.98, X4 Pharmaceuticals (XFOR) 2.32% +0.68, Autobot Holdings (ARBE) 8.92% +0.42, Gorilla Technology Group Inc (GRRR) 35.63% +0.29, Ocugen (OCGN) 2.92% +0.28, Plug Power (PLUG) 8.36% +0.22, Equinor (EQNR) 4.81% +0.21, Hecla Mining (HL) 0.58% +0.20, and SolarEdge (SEDG) 0.83% +0.19.
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$6
2025-02-13
Reason
Chardan Capital
Daniil Gataulin
Price Target
$6
2025-02-13
Maintains
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$6
2025-01-23
Reason
Chardan Capital
Daniil Gataulin
Price Target
$6
2025-01-23
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ocugen Inc (OCGN.O) is -4.81, compared to its 5-year average forward P/E of -27.04. For a more detailed relative valuation and DCF analysis to assess Ocugen Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.04
Current PE
-4.81
Overvalued PE
73.48
Undervalued PE
-127.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
133.10
Current PS
202.99
Overvalued PS
367.92
Undervalued PS
-101.71

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

OCGN News & Events

Events Timeline

(ET)
2025-06-16
07:04:49
Ocugen announces U.S. FDA cleared the IND amendment to initiate Phase 2/3 trial
select
2025-06-05 (ET)
2025-06-05
07:04:49
Ocugen announcing signing of term sheet, enter licensing agreement for OCU400
select
2025-05-27 (ET)
2025-05-27
07:04:50
Ocugen receives Rare Pediatric Disease Designation for OCU410ST
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-16Benzinga
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial

  • FDA Clearance for Clinical Trial: Ocugen Inc has received FDA clearance to start a Phase 2/3 trial for its gene therapy OCU410ST, aimed at treating Stargardt disease, which affects around 100,000 individuals in the U.S. and Europe.

  • Stock Performance: Following the news, Ocugen's shares rose by 4.5% to $1.18, with notable short interest in the stock, indicating investor skepticism about its future performance.

Preview
9.0
06-16NASDAQ.COM
Ocugen Says FDA Cleared IND Amendment To Initiate Phase 2/3 Study Of OCU410ST In Stargardt Disease

  • FDA Approval for Clinical Study: Ocugen, Inc. has received FDA clearance to initiate a Phase 2/3 study of its gene therapy candidate OCU410ST for treating Stargardt disease, a genetic condition causing vision loss.

  • Study Details and Future Plans: The study will involve 34 participants receiving a subretinal injection of OCU410ST, with plans to submit a Biologics License Application by 2027 after previously obtaining Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment.

Preview
9.0
06-16Newsfilter
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

  • FDA Approval for Clinical Trial: Ocugen, Inc. has received FDA clearance to initiate a Phase 2/3 clinical trial for OCU410ST, a gene therapy aimed at treating Stargardt disease, which affects vision in children and young adults. The trial will enroll 51 participants to evaluate the therapy's effectiveness and safety.

  • Positive Preliminary Results: Previous Phase 1 trial data showed OCU410ST had a favorable safety profile and resulted in significant improvements in visual function and slower lesion growth in treated patients compared to untreated controls, highlighting its potential as a treatment option for this genetic eye disorder.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ocugen Inc (OCGN) stock price today?

The current price of OCGN is 1.09 USD — it has increased 0 % in the last trading day.

arrow icon

What is Ocugen Inc (OCGN)'s business?

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.

arrow icon

What is the price predicton of OCGN Stock?

Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 6.33 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ocugen Inc (OCGN)'s revenue for the last quarter?

Ocugen Inc revenue for the last quarter amounts to 1.48M USD, increased 46.06 % YoY.

arrow icon

What is Ocugen Inc (OCGN)'s earnings per share (EPS) for the last quarter?

Ocugen Inc. EPS for the last quarter amounts to -0.05 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ocugen Inc (OCGN)'s fundamentals?

The market is revising Upward the revenue expectations for Ocugen, Inc. (OCGN) for FY2025, with the revenue forecasts being adjusted by 69.85% over the past three months. During the same period, the stock price has changed by 98.58%.
arrow icon

How many employees does Ocugen Inc (OCGN). have?

Ocugen Inc (OCGN) has 95 emplpoyees as of June 20 2025.

arrow icon

What is Ocugen Inc (OCGN) market cap?

Today OCGN has the market capitalization of 318.31M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free